Clearmind enrolls first AUD patients in CMND-100 clinical trial

PUBT · 2d ago
Clearmind enrolls first AUD patients in CMND-100 clinical trial
  • Clearmind Medicine enrolled the first Alcohol Use Disorder patients in its CMND-100 clinical trial.
  • Results have not been presented; the study will generate future safety and early efficacy readouts.
  • First dosing in AUD patients marks the initial test of CMND-100 in the target condition, following prior healthy-volunteer dosing.
  • Trial aims to assess whether CMND-100 can be administered safely while showing early signs of reducing harmful alcohol use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110800PRIMZONEFULLFEED9825241) on September 11, 2026, and is solely responsible for the information contained therein.